Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fewer Observations, Shift In Emphasis Seen In FDA's Pandemic-Reduced Inspections

Executive Summary

US agency mostly saw less of the same when it scaled back inspectional activity during COVID-19, but observed more training and equipment issues.

You may also be interested in...



How The US FDA’s Inspectional Approach Is Shifting For The Post-Pandemic Era

Agency hints of a “hybrid” future of in-person inspections supplemented by alternative tools like remote interactive evaluations.

What To Do When Last Pandemic’s Answer To The Next Pandemic Falters: Point Fingers

US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.

Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders

Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS145154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel